Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression. Methods: This Phase 3, double-blind, multicenter study enrolled adults with moderate-to-severe depression and nonresponse to ≥2 antidepressants in the current depression episode. Eligible patients (N = 346) were randomized (1:1:1) to twice-weekly nasal spray treatment (esketamine [56 or 84 mg] or placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4 weeks. The primary efficacy endpoint was change from baseline to day 28 in the Montgomery-Asberg Depression Rating Scale total score, performed by blinded, remote raters. Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. Results: Statistical significance was not achieved with esketamine 84 mg/antidepressant compared with antidepressant/placebo (least squares [LS] means difference [95% CI]: –3.2 [–6.88, 0.45]; 2-sided P value = .088). Although esketamine 56 mg/antidepressant could not be formally tested, the LS means difference was –4.1 [–7.67, –0.49] (nominal 2-sided P value = .027). The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache. Conclusions: Statistical significance was not achieved for the primary endpoint; nevertheless, the treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo. Safety was similar between esketamine/antidepressant groups and no new dose-related safety concerns were identified. This study provides supportive evidence for the safety and efficacy of esketamine nasal spray as a new, rapid-acting antidepressant for patients with treatment-resistant depression. Trial Registration: ClinicalTrials.gov identifier: NCT02417064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least squares mean change (±SE) in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time in double-blind phase (observed cases mixed model for repeated measures [MMRM]). LS, least squares; SE, standard error. LS mean and SE were based on MMRM with change from baseline as the response variable and the fixed effect model terms for treatment (esketamine 56 mg/antidepressant, esketamine 84 mg/antidepressant, antidepressant/placebo), day, region, class of oral antidepressant, and treatment-by-day, and baseline value as a covariate. Results are not adjusted for multiple comparisons or sample size reestimation. Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/2c4f045dfb03494db68f2585854e303a/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials found that esketamine, in combination with an oral antidepressant, rapidly reduced suicidal thoughts compared to placebo in adults with TRD who were at imminent risk for suicide [65,88,89].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [152]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because this was statistically tested when it should not have been, it introduced some spin into the published report [9], despite the numerical results being deemed reproducible.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In patients who respond to biogenic amine antidepressants, the time to onset of effect is typically 3 to 7 weeks, during which time patients remain symptomatic and at risk of self-harm (Rush et al., 2006).”
BackgroundSelf-citationDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“About one-third of patients with MDD fail to achieve remission despite treatment with multiple biogenic amine (e.g., serotonin, norepinephrine) antidepressants and hence have treatment-resistant depression (TRD) (Fava, 2003).”
BackgroundMethodInfluentialSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPosner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Items 601–679 of 679
Uso de esketamina en depresión resistente al tratamiento: una revisión exploratoria sistemática
Rotta, C. E. D., Cornejo, E. S., Huayanay, L., & Vargas-Murga, H. (2025) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v88i3.6424
Hack, L. M., Zhang, X., & Williams, L. M. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_12
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Human in vivo assessment of ketamine binding of the serotonin transporter—follow up at a higher dose
Schlosser, G., Murgaš, M., Godbersen, G. M., Reichel, S., Silberbauer, L., Nics, L., Winkler, D., Stimpfl, T., Hacker, M., Kasper, S. F., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1651016
Indu, V., Chandra, Y. P., & Kavyasudha, K. (2025) · International Journal of Pharmaceutical Research and Development · doi:10.33545/26646862.2025.v7.i2e.203
Viana, V. G., de Lima, D. R. S., Rodrigues, D. R., Filho, J. G. S., Bandeira, S. R. D. J., Barbieri, C. A., Alves, A. D. S., da Silva, L. L. D. A. R., SILVA, L. C. A. D. M. P. S. D., Lourenço, J. V. E. F., et al. (2025) · Seven Global Congress of Multidisciplinary Studies · doi:10.56238/1stcongresssevenmultidisciplinarystudies-282
Wellington, N. J., Quigley, B. L., Bouças, A. P., Dutton, M., Can, A., Lagopoulos, J., & Kuballa, A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120791
Effects of Ketamine and Related New Psychoactive Substances in Rat Urinary Bladder
Gant, A. (2024) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.27978
Cetamina: um psicadélico em ascensão na depressão resistente ao tratamento
Santos, P. E. D. S. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/4crx-c978
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · Figshare · doi:10.6084/m9.figshare.19802441
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · Figshare · doi:10.6084/m9.figshare.19802426
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · Figshare · doi:10.6084/m9.figshare.19802432
Ramming, H., Theuerkauf, L., Hoos, O., Lichter, K., & Kittel-Schneider, S. (2024) · Figshare · doi:10.6084/m9.figshare.25929072
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · Figshare · doi:10.6084/m9.figshare.19802429
Jamieson, C., Popova, V., Daly, E., Cooper, K., Drevets, W. C., Rozjabek, H., & Singh, J. B. (2023) · Figshare · doi:10.6084/m9.figshare.22790569
Self-citationIntranasales Esketamin zur Behandlung der akuten Depression
Göldner, R. S. (2023) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-39316
Abordagem à Depressão Refratária
Mendonça, J. B. C. L. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/rzj6-7a49
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · Figshare · doi:10.6084/m9.figshare.19802438
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · Figshare · doi:10.6084/m9.figshare.19802435
A Presentation of Evidence and Effectiveness of Esketamine Treatments to Psychiatric Providers
Nango, M., & Nango, M. (2024) · UA Campus Repository (The University of Arizona)
Scotton, E. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Esketamin u liječenju terapijske rezistentne depresije
Vudrić, M. (2024) · Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)
Esketamina e Depressão Resistente ao Tratamento: Revisão Sistemática
Rato, M. A. B. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Γαρούφα, Χ.-Μ. Χ., & Γαρούφα, Χ.-Μ. Χ. (2025) · University of Thessaly Institutional Repository (University of Thessaly)
Research Progress on the Mechanism of Esketamine in Antidepressant Treatment
尹, 晓. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123667
Olaoluwa, I. F. (2025) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2025-16871
Zuo, M., Li, Y., Williams, J. P., Sun, L., Li, Y., Wang, R., Ren, G., Xu, Q., & An, J. (2026) · Sleep Medicine · doi:10.1016/j.sleep.2025.107317
Abordagem atual na seleção de medicamentos emergentes na Depressão Resistente
Martins, M. S. T. V. D. B. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Untersuchung der Selbstmanagementfähigkeit depressiver Patienten
Schnierer, N. (2026) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00037911
Esketamine use for treatment-resistant depression: a scoping review
Rotta, C. E. D., & Cornejo, E. S. (2024) · Universidad Peruana Cayetano Heredia Institutional Repository
Residual atypical psychotic disorder and neuroborreliosis: a case report
Milasauskiene, E., & Steiblienė, V. (2021) · Lithuanian University of Health Sciences
Lejman, A., Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Mazurkiewicz, A., Sidor, H., & Wołosik, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4697
Zhou, M., Qi, Y., Zhou, F., Wu, H., Chen, J., Wang, L., & Wang, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1746121
Guffanti, A., Leonardi, M., Brondino, N., Dell’Osso, B. M., Martiadis, V., & Olivola, M. (2026) · Clinics and Practice · doi:10.3390/clinpract16030061
Vanskeligt Behandlelig depression:National Klinisk Retningslinje
Videbech, P., Martiny, K., Gbyl, K., Jørgensen, M. B., Møller, S. B., Hjerrild, S., Straszek, S. P. V., Austin, S. F., Welcher, B., Sørensen, C. H., et al. (2020) · Research at the University of Copenhagen (University of Copenhagen)
Gallardo, L. M. (2026) · Preprints.org · doi:10.20944/preprints202604.0415.v1
Impact et faisabilité du partage des données individuelles issues de la recherche clinique
Pellen, C. (2024) · theses.fr (ABES) · doi:10.70675/ef81f3a2z0c0cz4757za338z831065d04fdc
Psychedelics: Future Therapeutics in Major Depression?
Olivier, B., & Olivier, J. D. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_25
ESKETAMINE AND DEEP BRAIN STIMULATION IN TREATMENT-RESISTANT DEPRESSION: A LITERATURE REVIEW
Wiśniewska, J., Wiśniewski, M., Buczek, W., Bartnik, P., Barzyk, K., & Pietrzak, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5003
Kosiarski, B., Skrzypek, A., Markowicz, P., Zbrożek, M., Biłyk, K., Hutkowski, M., Chwostek, Z., Maruchniak, H., Marzec, W., & Biedroń, P. (2026) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/221219
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551944.bm01
Thomas, A. G., Palaniappan, D., Guruswamy, S., & SASHIKAR, A. C. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.59s.166
Haubman, J. L., da Silva, J. O. C., de Moura, B. H. L. M., Vargas, P. D. V., Garcia, A. R., Zambrin, M. E. G. C., Kummer, M. L., Scherer, G. M., Bugs, T. N., & Schvartz, H. V. (2026) · Open Minds International Journal · doi:10.22533/at.ed.51572142603075
Treating addiction with an addictive drug: the ketamine paradox revisited
Hakami, A. Y. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1866092
Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response
Serretti, A. (2026) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.26.1487
Wu, Q., Li, W., Luo, Z., Wang, C., Lan, X., Shen, J., Chen, Z. X., Pan, J., Liu, X., Zhu, H., et al. (2026) · BMC Psychiatry · doi:10.21203/rs.3.rs-10020524/v1
The functional role of ERK activity in esketamine's antidepressant effects
Zhang, P. X., Wu, M., Zhang, K., He, J., Liu, X., Zhang, H., Hu, A. Z., & Zhou, W. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174248
THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
Kotlarski, W., Kotlarska, K. M., Mainka, T. S., & Sergejuk, E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5523
Chen, L., Chen, Y., Zhao, Y., Feng, T., Song, X., Xie, F., Shen, J., He, J., Guo, J., & Zhong, L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1781915
Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.
Fremont, R., Corwin, M., Kandel, G., Talati, E., Denkiewicz, J., Sustana, R. L. D. H., Bachi, K., & Feder, A. (2026) · PubMed Central · doi:10.1176/appi.focus.20250046
DEPRESSÃO RESISTENTE AO TRATAMENTO: QUANDO ESCALAR A TERAPIA E REPENSAR O DIAGNÓSTICO
Bento, Y. S. G. M., Campos, N. B. F. L. B., Mota, M. F. P., Prado, M. J. A., & Neves, M. D. A. M. (2026) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v12i8.29427
Couto, M. A. S., Januário, F. E. P., Pinheiro, G. D. L. C., Neves, R. D. C., Malaquias, D. T. M., de Melo, J. F., Carvalho, R. D. O., Carvalho, S. A. D. S., Botelho, M. V. B. R., Garcia, F. J. L., et al. (2026) · International Journal of Pharma Insight Studies · doi:10.54660/ijpis.2026.3.4.29-41
Farias, G., Chahinian, H., Hauchard, N., Brunet, D., Fantini, J., Yahi, N., Fantini, D., & Aulas, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080987
Lee, J. G., & Park, Y.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_11
Kallarackal, J., Dyer, B. J., & Huang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_36
New treatments for treatment-resistant depression: esketamine controversies – a narrative review
Vinberg, M. (2026) · Danish Medical Journal · doi:10.61409/a02260078
Nikolin, S., Pande, S. R., Lennon, M. J., Moffa, A. H., Cao, T. V., Tan, C., Harvey, A. J., Shiroma, P. R., Glue, P., Loo, C. K. A., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7445299
Benster, L. L. (2026) · eScholarship (California Digital Library)
ประสิทธิภาพและความปลอดภัยในการใช้เคตามีน และเอสเคตามีนในการรักษาโรคซึมเศร้า
Rattanasumawong, W., & Ittasakul, P. (2020) · Journal of the Psychiatric Association of Thailand
Deschênes, P. J. F., Lam, C., Nahi, W., Nguyen, D. S., & Vincent, P. D. (2021) · Pharmactuel
Eldy, E., Setiawan, A. A., Sabhinaya, S., Supinto, P. A., & Tjahyanto, T. (2023) · PREPOTIF Jurnal Kesehatan Masyarakat
Gayathri, H., Nivedhya, J., Purushothama Reddy, K., Dawn, V. J., Surabhi Mohan, K., John, E. M., & Thomas, S. C. (2026) · International Journal of Pharmaceutical and Clinical Research · doi:10.33545/26647591.2026.v8.i10a.224
Psychometric Properties of the 3-Item Clinician Administered Dissociative States Scale (CADSS)
Bremner, J. D., & Vaccarino, V. (2026) · Chronic Stress · doi:10.1177/24705470261497666
Mathai, D. S., Pilecki, B. C., Zaki, H., Morris, T., Morris, M., & Garcia‐Romeu, A. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100046
Szawarnoga, D., Fojcik, J., Górski, M. K., & Krzystanek, M. (2026) · Pharmaceuticals · doi:10.3390/ph19101644
Xiao, C., Xu, X., Yao, W., Pan, Y., Wan, S., Wei, J., & Xu, L. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.10.038
Lapa, C. D. O., Juruena, M. F., Pereira, D. C., Furlanetto, K., Castiglioni, M. C. M., Arturi, V., Viola, T. W., & Spanemberg, L. (2026) · Research Square · doi:10.21203/rs.3.rs-11132874/v1
Gao, K., Oruc, E. B., & Koparal, B. (2026) · Medicina · doi:10.3390/medicina62112198
Abdel-Wahab, M., Okasha, T., Shaheen, M., Nasr, M., Molokheya, T., Omar, A. E., Rabie, M. A., Samy, V., Hamed, H., & Ali, M. (2022) · doi:10.3389/fpsyt.2022.797150.s001
Marchi, M., Magarini, F. M., Galli, G., Mordenti, F., Travascio, A., Uberti, D., Micheli, E. D., Pingani, L., Ferrari, S., & Galeazzi, G. M. (2022) · doi:10.3389/fnins.2022.1011103.s001
Oliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N., & Mulhern-Haughey, S. (2023) · doi:10.3389/fpsyt.2023.1250987.s002
Rothärmel, M., Benosman, C., El-Hage, W., Berjamin, C., Ribayrol, D., Guillin, O., Gaillard, R., Berkovitch, L., & Moulier, V. (2022) · doi:10.3389/fpsyt.2022.865466.s001
Self-citationWang, X., Ma, J., Ren, S., & Hu, L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1995965
Ketamine after the hype: What are we actually treating?
Movahed, P. (2026) · Australasian Psychiatry · doi:10.1177/10398562261508726
Metadata
- Authors
- Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. V. D., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B.
- Affiliations
- Janssen Research and Development, Department of Neuroscience, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Janssen Research and Development, Clinical Biostatistics, Titusville, New Jersey
- University of Ottawa (CA)
- Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts
- Medical Research Network (US)
- University of Toronto (CA)
- Centre Hospitalier Sainte Anne, Service Hospitalo-Universitaire, Paris, France
- AZ Sint-Jan (BE)
- University of Kansas (US)
- Janssen Research and Development, Department of Neuroscience, San Diego, California
- Corresponding author
- Fedgchin, Maggie
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-10
- Volume
- 22
- Issue
- 10
- Pages
- 616-630
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822141
- OpenAlex
- W2961020354
- Semantic Scholar
- 3739b211f156e1c4836c25e44222f6497502cdd7
- Cited by
- 606
- References
- 32
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 58 · 2023: 59 · 2022: 72 · 2021: 62 · 2020: 222 · 2019: 10
- FWCI
- 56.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant combination therapy, rapid-acting antidepressants, antidepressant non-response, depression remission, adverse events, dissociation, nausea
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Antidepressive Agents, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Citalopram, Treatment Outcome, Sertraline, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.